No phase III benefit with selumetinib in KRAS-mutant NSCLC
No phase III benefit with selumetinib in KRAS-mu
No phase III benefit with selumetinib in KRAS-mu
SCLC: genomic alterations pave the way to target
Rare driver mutations: encouraging results in sm
Preface – ESMO 2016 Silvia Novello, MD, PhD,